Intensity Therapeutics Wins 2026 Cancer Treatment Technology Innovator Award
Intensity Therapeutics received the Cancer Treatment Technology Innovator of the Year 2026 – USA award for its proprietary INT230-6 non-covalent intratumoral drug-conjugation technology. The late-stage clinical therapy has demonstrated encouraging outcomes in advanced sarcoma and breast cancer patients with no remaining treatment options.
1. Award Recognition
On May 14, 2026, Intensity Therapeutics was named the Cancer Treatment Technology Innovator of the Year – USA at the 2026 Healthcare & Pharmaceutical Awards, highlighting its leadership in intratumoral injection drug delivery.
2. Novel Drug Technology
INT230-6, discovered using the proprietary DfuseRx platform, combines cisplatin, vinblastine sulfate and a diffusion enhancer (SHAO) via non-covalent conjugation to maximize tumor penetration, retain cytotoxic agents within the lesion and minimize off-target toxicity.
3. Clinical and Market Implications
In over 200 patients across Phase 1/2 and Phase 2 trials, INT230-6 showed encouraging tumor-killing and immune activation in metastatic sarcoma and locally advanced breast cancer, positioning the company to advance a Phase 3 soft tissue sarcoma study and bolster its chronic disease treatment paradigm.